Solutions
Inagene is a complete, managed precision prescribing program designed to integrate into existing benefit plans, disability management workflows, and care pathways to deliver genetic insight that improves medication decisions, reduces avoidable costs, and supports better outcomes for plan members.
01
With a simple at-home cheek swab, Inagene’s Canadian-based, CLIA and COLA accredited laboratory analyzes each member’s genetic profile across 48 genes and 123 variants, covering 240+ commonly prescribed medications. Inagene is one of Canada’s most comprehensive PGx panels, carefully benchmarking our targets against CPIC international medical standards. Results are delivered within 7–10 business days.
02
Test results are delivered through a secure portal accessible to both the plan member and their healthcare provider. The report identifies which medications are likely to work, which carry elevated risk, and which are unlikely to be effective — translated into clear, clinically actionable guidance rather than raw genetic data.
03
Every Inagene program includes access to a licensed pharmacist who can walk members and their care teams through test results, answer clinical questions, and support medication decision-making. This step is critical for ensuring genetic insights are understood and acted on.
04
The science of pharmacogenetics evolves continuously. Inagene updates its medication-gene associations quarterly, adding new evidence-based guidance as it becomes available. A test completed today continues to grow in clinical relevance over time.
05
Inagene’s managed program includes dedicated account management support: program design, launch communications, ongoing utilization tracking and reporting. Plan sponsors and unions, TPAs, and DM programs don’t have to drive adoption alone. Inagene provides the tools and support to reach the members who need it most.
06
Aggregate, anonymized utilization and outcomes data is provided on an ongoing basis, so your organization has the information needed to demonstrate program value, track clinical impact, and support the conversations that matter most to your clients.
Inagene’s testing protocols are based on leading pharmacogenomic guidelines including CPIC , DPWG, ClinPGx, FDA, CERSI-PGx, CPNDS, and others. We only add medication-gene associations that meet the most rigorous clinical evidence thresholds. We only provide actionable information that prescribers can confidently act on.
Inagene holds a Medical Device Establishment Licence (#9922) from Health Canada, meets ISO27001 standards, and our Toronto laboratory is independently accredited to the highest international clinical laboratory standards.
Accreditations
Pharmacogenetic testing has validated clinical applications across a broad range of conditions. The following therapeutic areas represent where medication trial-and-error most significantly affects plan member health, and where Inagene’s guidance delivers the clearest, most measurable outcomes.
Mental health conditions are the leading driver of disability claims in Canadian benefit plans, and antidepressants, anti-anxiety medications, and ADHD treatments have among the highest rates of genetic variability in how they’re processed. For plan members cycling through ineffective psychiatric medications, the personal and financial cost can span years. PGx-guided prescribing has been shown to increase the likelihood of remission from major depressive disorder by 78% — making this the highest-impact therapeutic area for most group benefit plans.
In the 2024 Benefits Canada Health Survey , 38% of plan members were officially diagnosed or self-diagnosed with chronic pain. Pain medications including opioids, anti-inflammatories, and nerve pain treatments, are among the most genetically variable drug classes. When the wrong medication is prescribed, members may fail to improve, or worse, they may experience serious adverse effects that extend absences or claims and complicate their care .
Blood thinners, statins, and blood pressure medications are among the most commonly prescribed drugs in Canada, and genetic variation significantly affects how they’re metabolized. For members on these medications who aren’t responding as expected, there is a risk in unmanaged cardiovascular disease that shows up downstream in claims, complications, and disability.
Canadian women live longer but spend 24% more of their lives in poor health than men — a gap that shows up directly in disability claims and benefit costs. Inagene’s panel covers genetic variants relevant to hormonal health, menstrual conditions, PMDD, postpartum mental health, menopause, and other women’s therapeutic areas where medication response is highly variable and where getting it right sooner has significant personal and plan-level impact.
Inagene’s panel covers 240+ medications across additional therapeutic areas including oncology, with new medication-gene associations added quarterly as the evidence base grows.
Ready to bring precision prescribing to your organization?